5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
about
Radiotherapy combination opportunities leveraging immunity for the next oncology practiceCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Myeloid-Derived Suppressor Cells in Bacterial InfectionsCancer immunotherapy: the beginning of the end of cancer?Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancerMetronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinomaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyModulation of APC Function and Anti-Tumor Immunity by Anti-Cancer DrugsThe impact of the myeloid response to radiation therapyHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsMyeloid-derived suppressor cells as therapeutic target in hematological malignanciesDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsMetronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung CancerCancer vaccinesRapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based VaccineTargeting Immune Regulatory Networks to Counteract Immune Suppression in CancerTargeting tumor-associated macrophages to combat pancreatic cancerPro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic TargetsThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacyMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedMyeloid-derived cells are key targets of tumor immunotherapyCoordinated regulation of myeloid cells by tumoursBleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cellsProspective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patientsDynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational studyMicroenvironmental regulation of therapeutic response in cancerThe innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.
P2860
Q26738443-E629E271-A824-4111-8BEE-58EDA002145AQ26745516-C1668892-0520-40A0-9300-2A6DEC523663Q26747695-66C2C540-DE29-437F-96DF-4B9E823E74C7Q26749373-37133120-B29F-4CBC-85D9-6EF24295D889Q26752277-9CC133C9-2C24-4EB1-9174-039E98E9AF94Q26752838-AD960024-4D8F-43D2-BF67-3CF0C6ADE9CEQ26753070-84BDF3DA-22B5-46AD-B708-CCEE101A8DF2Q26770391-EF96E2AF-1A95-45B9-97DD-443E4D26368BQ26777205-C3559340-B6C8-4801-8163-FFCC5BD49A8AQ26779184-B7816BC5-7783-4260-94F3-967ACEA55792Q26781522-8D8951CD-67AC-432E-A3F8-B1A976297E67Q26851643-5974E285-62E5-441D-8D69-04E552DCE1C8Q26863418-481AA1CD-D747-4B6A-A3D9-55DB907DEEF6Q26863779-C493CB53-BAE7-4459-9D77-266A19F828CBQ26865532-97AE7357-9652-4B7C-BBF2-9D29B7C69E58Q27010234-E7B8FAF4-447B-4312-922C-B2AA3FC7376EQ27014829-017CA9A1-F44D-416D-B3FD-CBC769FAEDC7Q27015786-0BF1B8A9-F777-4CCF-A6C7-7FC5337F8616Q27024438-6C68A8D8-A29E-4C75-B6F0-095FE19D7CA1Q27317214-0F063F7A-A4A3-407C-8699-81E1F3FA76F0Q28066486-CF6B6669-8D50-45A3-87F7-3681BDCF0CD5Q28076103-6AE1A81E-6E84-48AA-ABFE-ABEC7802465AQ28076161-9C13EB94-F38D-484E-A58C-F97F932649F2Q28076760-2736A880-9453-41E2-BE6B-9F4FEE727A92Q28078539-5995E2A6-6013-40BF-A9D1-995A4D156836Q28082461-BAEF8A66-23FC-47B5-8DC3-DF6C7BF096DFQ28084627-9AF92FA5-9126-458F-8F33-261196DCA227Q28388246-9FD1A64C-D48A-452A-ABDC-AA0284CC24D3Q28395157-7745C87E-0B42-451F-8645-5DAF8D30C3DFQ28533749-5715F80E-EB56-4E0E-8F3E-37CC9EE9082BQ28542660-FAFBE1FB-5B0C-4FFE-A4BC-5FD1BCFF5516Q30376149-869FD3F2-2719-4850-A511-293314B00C43Q30513468-0C98F6A9-5146-468C-9C64-D79A84EC0C42Q33429758-521A9DB6-7A1F-4565-8E35-A2EE51DDD0ADQ33560501-D60436C8-5D35-4F1F-BFAD-6D405BFD7A2DQ33606107-C99DE82D-CDE8-4B06-9FB9-462742DB81EFQ33612711-DDD660E2-D487-4D81-A2F5-50E780C4DE66Q33654609-C290DB38-E9E3-49B8-BEBE-1177FA6155A2Q33660069-B33255EE-3EA7-4B98-8CA1-765F191F7378Q33816141-6B1D6FB5-2CED-498D-8AEE-510D43521306
P2860
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@en
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@nl
type
label
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@en
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@nl
prefLabel
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@en
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@nl
P50
P1433
P1476
5-Fluorouracil selectively kil ...... -dependent antitumor immunity.
@en
P2093
Angélique Chevriaux
Fanny Chalmin
P304
P356
10.1158/0008-5472.CAN-09-3690
P407
P50
P577
2010-04-13T00:00:00Z